BB536 Probiotic: Benefits, Evidence, Dosage, and Safety

BB536 is not a general “probiotic”, but one that has been studied for more than 50 years and has multiple human randomized controlled trials.specific strains. Comprehensive as ofAugust 2026Based on human trials, mechanism experiments, safety data, regulatory data from Japan and the United States, and the latest research, a clear conclusion can be drawn:

The strongest evidence for BB536 is its ability to support the gut environment and improve bowel regularity in some people. Human studies also suggest possible effects on immune regulation, pollen allergy symptoms, and respiratory infections, although that evidence is weaker. Benefits for fat loss, healthy aging, cognition, and colorectal cancer prevention remain unproven.

And one of its important features is:There is a clear "responder/non-responder" difference, it's not that eating more will result in greater effects.

1. What exactly is BB536?

The full name is:

Bifidobacterium longum subsp. longum BB536
Chinese usually calls:

Bifidobacterium longum subsp. longum BB536 / Bifidobacterium longum BB536

It is a "strain", not a chemical composition.

That is to say:

Just because a product says "Bifidobacterium longum" does not mean it is equal to BB536.

BB536 inJune 1969Isolated from the stool of a healthy baby girl, currently deposited in ATCC, strain number:

ATCC BAA-999

The ATCC clearly documented its origin and BB536 strain identity.

The complete genome has now been sequenced:

GenBank：AP038757.1

Belong toB. longum subsp. longum。

Therefore, from the perspective of "clear strain identity", BB536 is one of the probiotics with fairly complete information.

2. Actual value and evidence rating of BB536

3. The most solid evidence at present: bowel movements and gut environment

This is the most commendable part of BB536.

1. Effects have been observed at 2 billion CFU/day

In a 1997 human study, 40 women consumed daily:

BB536 2 × 10⁹ CFU = 2 billion units/day

Lasts 3 weeks.

Results include:

The bowel movement frequency increased and the stool consistency improved; another group experiment found that the proportion of bifidobacteria in the stool increased, ammonia decreased, and the activity of some putrefaction-related enzymes decreased.

So from a historical perspective:

2 billion/day is not “too little”.

2. Japan currently uses about 2 billion in actual functional foods.

Among Morinaga's current BB536 products, many are based on:

BB536 2 billion CFU/day

As functional ingredient dosage.

In one representative study, constipation-prone adults consumed 2 billion BB536 for two weeks:

During the 2 weeks of the control period, bowel movements were approximately:

8.4 times

Issue BB536:

9.6 times

That is, on average:

An increase of about 1.2 bowel movements in two weeks.

There’s a statistical difference, but it’s also a good illustration of the real-world effects of probiotics:

The effect is closer to "making the originally infrequent bowel movements a little more regular" rather than going directly from severe constipation to once a day.

4. 50 billion has also been studied, but the effect has not become 10 times

This research is very important.

In 2023, the American Journal of Gastroenterology published a randomized, double-blind, placebo-controlled trial.

80 elderly people with chronic constipation with an average age of about 78 years old.

Dosage reaches:

5 × 10¹⁰ CFU/day

That is:

50 billion BB536/day

Lasts 4 weeks.

Result:

Primary endpoint - overall constipation score CSS:

There was no statistically significant difference between BB536 and placebo, P=0.074.

But among them:

The sub-item of bowel movement frequency improved significantly:

P=0.008

Difficulty passing stool also tends to improve.

This test revealed a very important message:

BB536 is not a typical dose-dependent drug.

2 billion might work.

5 billion might work.

50 billion is not necessarily 10 times better than 5 billion.

Therefore, there is no need for ordinary healthy people to pursue doses of 50 billion or 100 billion in order to "maximize the effect."

5. Newer randomized trials of 5 billion/day

There is also an interesting randomized double-blind crossover trial in 2022.

24 adults primarily prone to constipation used:

BB536 is about 5 × 10⁹ = 5 billion CFU/day

Use special acid-resistant capsules.

Lasts 2 weeks.

In the second week, the frequency of bowel movements in the BB536 group increased significantly compared to the placebo:

ITT analysis:

P=0.0334

PP analysis:

P=0.0492。

And the research found:

The effects vary greatly from person to person.

Researchers were even able to use pre-dose:

Gut flora + fecal metabolites

Prediction to a certain extent:

This is also an increasingly important concept in the probiotic field:

Not everyone will get the same effect from taking probiotics.

6. Why might BB536 improve bowel regularity?

It does not irritate the intestines like stimulant laxatives.

It may mainly go through several stages.

BB536 utilizes carbohydrates in the intestines to ferment and can form:

Metabolites such as acetic acid and lactic acid.

These metabolites, as well as "cross-feeding" with other bacteria, will change the local pH and microecology of the intestine.

BB536 itself is not a major butyrate-producing bacterium, but can affect:

Faecalibacterium and other bacteria

Thereby indirectly affecting metabolites such as butyric acid.

So it can be understood as:

This is not the same thing as "it enters the intestines and directly produces a certain magical substance."

7. Very interesting new discovery: Faecalibacterium

A 2024 randomized double-blind placebo study found that after healthy adults consumed fermented milk containing BB536:

ArriveDay 3, the relative abundance of Faecalibacterium was already higher than that of the control group.

This difference persisted until day 17.

At the same time in stool:

tryptophan

Indole-3-lactic acid

Indole-3-carbaldehyde (indole-3-aldehyde)

Metabolites have changed.

This point deserves attention.

Because these tryptophan derivatives are related to:

Intestinal barrier, immune regulation, AhR signaling, etc.

There is a biological link.

But make a special distinction:

"These metabolites have become better" ≠ It has been proven that people will be less likely to suffer from certain diseases as a result.

This is mechanistic evidence, not final clinical outcome.

8. Can BB536 really reach the large intestine alive?

This is confirmed.

BB536 has better tolerance to acid and oxygen than many bifidobacteria. Therefore, Morinaga has long used it as a strain that "reaches the large intestine alive".

More importantly, recent studies have directly detected human stoolLive BB536。

In a randomized study in 2025:

Before administration, BB536 was undetectable in all subjects.

After consuming yogurt containing BB536:

Day 3:

approx.10^6.33 CFU/g stool

Day 17:

approx.10^6.16 CFU/g stool

PMA-qPCR also confirmed the presence of viable bacteria.

Therefore, "passing through the gastrointestinal tract alive" is not just an advertising slogan.

9. However, capsule technology has a great impact

One study of BB536 acid-resistant capsules conducted artificial gastric juice experiments.

pH：

1.2

Duration:

2 hours

Approximately: in special acid-resistant capsules:

90% of BB536 are still alive.

But it must be noted here:

This is:

BB536 + specific capsule technology

the result obtained.

It does not follow from this that:

So when choosing probiotic products:

Bacterial strain + viable count + dosage form

All are important.

10. Will it permanently colonize your intestines?

There is currently no reason to think that eating for a period of time will permanently establish a new BB536 colony.

A typical situation is:

It increases during taking and gradually decreases after stopping taking.

For example, a toxin-typeBacteroides fragilisIn the study, the number of target bacteria decreased during BB536 intake, but gradually returned to close to the original level after stopping BB536.

So probiotics are more like:

instead of:

11. BB536 and “bad bacteria”

Earlier human studies found:

At high doses of BB536:

Enterobacteriaceae

and

Clostridium perfringens

There is a downward trend.

At the same time, fecal ammonia and other putrefaction products decreased.

Another very interesting one is:

ETBF - Enterotoxigenic Bacteroides fragilis

ETBF is thought to be associated with intestinal inflammation and colorectal cancer risk.

In a study of 32 healthy adults with ETBF, ETBF decreased after ingestion of BB536.

It went back up after stopping the intake.

But never translate this result into:

"BB536 prevents colorectal cancer."

There is a whole level of evidence difference between the two.

Currently it can be said:

cannot say:

12. Immune system: It has a role, but don’t simply understand it as “enhancing immunity”

There is a good randomized double-blind placebo trial in 2024.

About 100 healthy adults daily:

10 billion BB536

Duration:

4 weeks

The results showed that peripheral blood plasmacytoid dendritic cells:

pDC

Superficial:

CD86

The degree of activation was significantly increased relative to placebo.

In vitro experiments also observed:

Increased IFN-γ,

IFN-α1 and IFN-β tend to increase.

This means:

BB536 does affect immune signaling.

But not all other indicators have improved.

For example, NK cell activity in this study of healthy adults:

No significant advantage of BB536 over placebo emerged.

So "immune regulation" is much more accurate than "enhancing immunity".

13. Respiratory tract infections in children

A relatively large study well worth watching.

520 Malaysian preschool children aged 2 to 6 years old.

Every day:

5 billion BB536

Length:

10 months

The study initially recruited 520 people, but only 219 were fully compliant with the protocol analysis.

Result:

for diarrhea

No significant preventive effect was found.

for upper respiratory tract diseases

The number of attacks has decreased.

Sore throat duration:

Reduced by approximately 46%, P=0.018

Fever, runny nose, and cough also showed a downward trend, but some did not reach P<0.05.

Therefore:

"It may reduce some of the burden of respiratory diseases" is a reasonable statement.

But it cannot be said:

"BB536 can prevent colds."

14. The elderly and influenza

In one very small study, 27 people with an average age of about 87 took:

100 billion BB536/day

Also receive a flu shot.

In the follow-up period, the proportion of influenza and fever in the BB536 group was lower, and some changes in NK cell and neutrophil indicators were observed.

But sample:

There are only 27 people.

And the design isn't very clean either.

So this result is worth studying, but it is not enough for healthy adults to swallow 100 billion BB536 every day to prevent influenza.

15. Japanese cedar pollen allergy

This is actually an area that BB536 has studied more.

There were several items from 2006 to 2007:

Randomized, double-blind, placebo-controlled study.

For example, 44 patients with cedar hay fever took BB536 for 13 consecutive weeks.

Research found:

Runny nose, nasal congestion, and overall symptom score decreased,

There are also fewer people who quit taking medications early because of severe symptoms.

Changes in Th2-related immune indicators were also observed.

Another controlled pollen exposure experiment:

24 people,

BB536 is approximately:

50 billion×2 times/day

That is:

About 100 billion/day

4 weeks.

Ocular symptoms and subsequent medication use decreased.

So:

BB536 is not completely unfounded for cedar hay fever.

But these studies:

The sample size is smaller and older, and many studies are related to Morinaga.

Taken together, the level of evidence is approximately:

Medium to low to medium.

16. There is also a very important negative evidence: EFSA does not recognize these health claims

In 2011, the European Food Safety Authority EFSA systematically evaluated three health claims of BB536:

Improve bowel movements;

Reduce potentially harmful intestinal bacteria;

Improves normal resistance to cedar pollen allergens.

EFSA’s conclusions at the time were:

Not enough causal relationships are established.

Specifically pointing out the existence of some early bowel-movement studies:

There is no randomization, no blinding, and the design does not allow the elimination of time effects, multiple comparisons and other issues.

However, a fair explanation is also needed here:

This is2011 assessment。

Since then, new randomized controlled studies have appeared in 2022, 2023, and 2024.

Therefore, we cannot use the 2011 EFSA opinion to say "BB536 is invalid".

A more accurate statement is:

17. Ulcerative colitis

This is another area that can easily be amplified by marketing.

56 patients with mildly to moderately active ulcerative colitis.

BB536 dose is very high:

2～3 × 10¹¹ CFU/day

That is:

200-300 billion/day

Lasts 8 weeks.

Clinical remission rate:

BB536：

63%

Placebo:

52%

Difference:

P=0.395

No significance.

Although the UCDAI and endoscopic index of the BB536 group have improved, but:

Core between-group clinical response outcomes were not successful.

So now we can’t say:

BB536 is effective in treating ulcerative colitis.

18. IBS

There are some positive results, but the problem is that it is often used with other ingredients.

For example:

BB536 + Lactobacillus rhamnosusHN001 + Vitamin B6

In a randomized crossover trial of 25 IBS patients, abdominal pain and bloating improved.

But because:

HN001

and

Vitamin B6

So it cannot be proved:

How much of the effect comes from BB536.

This type of study is not sufficient to prove that BB536 alone is effective.

19. Fat loss and visceral fat

Same problem here.

A 16-week randomized controlled trial in 2024 on 100 adults with a BMI of 23 to 30:

Every day:

BB536：

10 billion

MCC1274：

5 billion

Result:

total abdominal fat,

visceral fat,

Triglycerides

Improved over placebo.

But this is:

BB536 + MCC1274

Not BB536 alone.

Therefore it cannot be concluded that:

The "Bifidobacterium Belly Fat Reduction" product that appeared in Japan in 2026 is also this combination.

20. Can BB536 improve memory and cognitive ability?

This is especially important to note for those focusing on the “cognitive functional component.”

There is currently no reliable evidence that BB536 alone can improve people's cognitive abilities.

There was a study of 38 healthy older adults:

BB536

M-63

M-16V

B-3

Four types of Bifidobacteria, each:

12.5 billion CFU

And do resistance training at the same time.

After 12 weeks:

MoCA cognitive score:

Both groups improved.

Differences between groups on the Flanker cognitive test:

P=0.056

The traditional P<0.05 criterion was not reached.

Therefore:

This study cannot be counted as cognitive evidence for BB536.

If the goal is "memory/cognition", what really deserves attention in Morinaga's system is:

Bifidobacterium breve MCC1274

Instead of BB536.

The two bacteria can easily be confused.

21. The latest “anti-aging” research in 2026

A related new study emerged in May 2026.

A randomized study of 48 overweight men aged 50 to 74 was published in May 2026.

Every day in the intervention group:

100g of yogurt containing 2 billion BB536

At the same time:

dietary guidance

Sports coaching.

After 12 weeks, a DNA methylation aging speed indicator:

DunedinPACE

Shows a decrease in the rate of aging by approximately:

2.2%～2.3%。

Sounds awesome.

But there's a huge problem:

There is no separate group for BB536.

The intervention is actually:

The control group did nothing.

And the research is:

Open-label, exploratory study with no single prespecified primary endpoint.

Therefore, it cannot be said at all at present:

BB536 reduces the aging rate of the human body by 2.3%.

All I can say is:

It is very easy for such news headlines to go further than the conclusion of the paper.

22. There will be another “high-protein athlete” trial in 2026

This is a very new randomized controlled trial of BB536.

60 young male athletes.

Eat a high-protein diet daily while taking:

46 billion BB536/day

4 weeks.

Across the entire study population:

gastrointestinal symptoms,

intestinal flora,

Metabolites

There were no significant BB536 vs placebo differences.

Internal diarrhea scores decreased only in the BB536 group, but relative to placebo:

There was still no significant between-group advantage.

Later enterotype subgroup analysis yielded some interesting results, but these were:

Post-hoc exploration afterwards.

The paper itself clearly defines these results as hypothesis-generating, rather than confirmed therapeutic effects.

This proves once again:

46 billion does not mean it is necessarily more effective than 2 billion.

23. The most likely mechanism of action of BB536

Based on the existing data, what is really worthy of attention in BB536 is not a certain "magic molecule", but the following chain of action:

This is more consistent with current research than "BB536 produces XX, so it enhances immunity."

The 2019 review of BB536 also includes:

gut microbiome modulation

That is, "intestinal microbial ecological regulation"

considered to be the main core mechanism explaining its diverse effects.

24. How is the safety?

Overall:

Very good.

BB536 has been used in food for decades.

In the 2009 GRAS notification, the US FDA classified BB536 as a variety of food ingredients:

Up to 1×10¹⁰ CFU/serving

The conclusion that “FDA has no questions” was given.

In 2019, it also targeted full-term infant formula milk powder:

1×10⁸ CFU/g formula milk powder

Completing another GRAS notification, FDA also:

has no questions。

But it needs to be explained:

GRAS = Judgment of Safety.

Not:

FDA certified BB536 can treat constipation, improve immunity, and resist aging.

These are two completely different questions.

25. Supervision situation in Japan

BB536 also has a long history in Japan.

For example:

ビヒダスプレーンヨーグルト

In 2000, we obtained the Food for Specific Health Use (Tokota) license.

Its recognition includes:

Contains live BB536,

Increase intestinal bifidobacteria,

Improve gut environment,

Adjust gastrointestinal condition.

Daily reference amount:

100g。

This carries more weight than an ordinary “health product advertisement.”

But now many products belong to:

Functional food

This system is different from special protection.

For example, Morinaga’s current BB536 capsules:

1 capsule per day:

5 billion BB536

Issue number:

J471

The statement is:

Improve the gut environment of the large intestine and regulate the intestines.

Functionally indicating food is a system for companies to submit scientific evidence. It does not mean that the Japanese government proves "this product must be effective" one by one.

26. Common side effects

It is generally well tolerated by healthy adults.

In the 50 billion/day randomized trial of chronic constipation in the elderly:

There were no differences in serious adverse events between BB536 and placebo.

Diarrhea events occurred in each group, but none were determined to be caused by BB536.

What is more likely to happen in reality is:

mild abdominal distension,

Increased farting,

The stool becomes soft,

Occasional diarrhea.

Usually it is a change in the intestinal fermentation environment.

If healthy people have obvious persistent diarrhea, pain or other abnormalities, there is no need to eat hard.

In addition, like all live probiotics, special populations such as severely immunocompromised, critically ill hospitalized, and those with central venous catheters should not interpret "probiotics are safe" as completely zero risk. It is best to make a judgment first with a doctor.

27. How much is reasonable to eat?

Based on the existing human trials of BB536, the different doses can be understood as:

2 billion CFU/day:
The valid range has been reached for some gut-health and bowel-movement studies.

5 billion CFU/day:
It is a very reasonable daily dose, supported by modern randomized studies. The current dose of BB536 capsules in Japan is also this dose.

10 billion CFU/day:
It is often used in immunity or mechanism research, and also falls within the scope of reasonable human trials.

More than 50 billion:
Human studies are useful, but they don't prove that the average person is significantly better than 5 billion.

100 billion to 300 billion:
It only appears in some allergy and disease studies, and there is no reason for ordinary healthy people to use this dose on a daily basis.

So for average healthy adults, if the purpose is just to:

Adjust gut environment/bowel movements

A more reasonable range is:

If you don't feel anything after eating 5 billion for several weeks, it is not the most reasonable way to directly upgrade to 50 billion.

Because it's possible:

Individuals themselves may be low responders.

28. How long does it take to judge whether it is useful?

Based on human trials:

Changes in gut microbiome:

It can be detected in about 3 days.

Changes in bowel movements:

Usually:

1 to 2 weeks

Ability to identify trends.

A more complete observation period:

2 to 4 weeks.

So if a healthy adult is having a bowel movement:

Consecutive consumption for 2 to 4 weeks is enough to determine whether you are a BB536 responder.

There is no need to say:

“You have to take probiotics for three months and a half to feel the effects.”

At least that's not the case with BB536's evidence on bowel regularity.

29. Yogurt, powder or capsule?

If the amount of viable bacteria is the same, it does not necessarily mean that "yoghurt is definitely stronger than capsules" or vice versa.

The key is:

Is it the BB536 strain?

How many CFU can be guaranteed at the end of the shelf life?

Storage conditions

Gastrointestinal survival rate

Is there acid-resistant technology?

Special acid-resistant capsules have the advantage of surviving gastric acid.

Yogurt is protected by a food matrix, and you can also get nutrients such as protein and calcium at the same time.

So if just for the BB536 itself:

Capsules are very convenient.

If you are willing to eat yogurt:

BB536 yogurt is also totally fine.

30. An easy trap: BB536 + other ingredients

Often seen on the market:

BB536 + Lactulose

BB536 + MCC1274

BB536 + other bifidobacteria

BB536 + HN001

Wait.

At this time, it is seen that the clinical results cannot be automatically attributed to BB536.

For example, now Morinaga's "Banton Improvement" yogurt:

BB536：

2 billion

Lactulose:

4g

Lactulose itself is a strong prebiotic and also increases bifidobacteria and bowel movements.

So:

31. The biggest weakness of BB536 research

This is something that must be said when evaluating this ingredient.

BB536 is a strain developed and commercialized by Morinaga Dairy.

Many important studies:

The author himself is an employee of Morinaga,

Research products provided by Morinaga,

Part of the research was funded by Morinaga.

For example, the 2024 immunity study and the 2026 athlete study both clearly disclosed this.

This does not mean:

The study is fake.

But it means:

At present, the biggest advantages of BB536 are:

There are numerous human trials and a long history of use.

One of the biggest shortcomings is:

Much of the evidence comes from the strain development companies themselves.

32. Final evaluation after removing marketing

BB536 is not the kind of "packaged probiotic with little evidence".

It is indeed a:

It is a mature probiotic strain with a clear strain, a long history, sufficient safety data, multiple human RCTs, and a history of actual Japanese food application.

In the field of probiotics, where the quality of evidence generally varies, it is one of the more advanced strains.

But it’s not as “one-size-fits-all” as the marketing materials make it out to be.

The most trustworthy ones right now are:

Followed by:

The following should not be used as the main reasons to buy BB536 at present:

In particular, it is necessary to combine BB536 with"Cognition, memory, concentration" componentsDistinguish between:

BB536 is currently not considered a cognitive-enhancing ingredient with reliable human evidence.

It should rather be classified as:

"Probiotics with strong evidence of intestinal health and some research on immune regulation"

instead of:

"Brain Function Probiotics".